Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Crossed cerebellar diaschisis (CCD) can be associated with impaired cerebrovascular reactivity (CVR) and poor clinical outcome, but whether this holds true for patients with diffuse glioma is unknown. With blood oxygenation level-dependent (BOLD)-CVR imaging, we determined the presence of CCD in patients with diffuse glioma and investigated its relationship with cerebrovascular reactivity and clinical outcome. For eighteen enrolled subjects (nineteen datasets) with diffuse glioma, CCD was deferred from BOLD-CVR using a predetermined cerebellar asymmetry index (CAI) cutoff value of 6.0%. A FET-PET study was done as a verification of the CCD diagnosis. BOLD-CVR values as well as clinical performance scores (i.e., Karnofsky performance score (KPS), disability rating scale (DRS), and modified Rankin scale (mRS)) by BOLD-CVR scan at 3-month clinical follow-up were assessed and compared for the CCD-positive and CCD-negative group. CCD was present in 26.3% of subjects and strongly associated with impaired BOLD-CVR of the affected (i.e., the hemisphere harboring the glioma) and unaffected supratentorial hemisphere (CCD(+) vs. CCD(-): 0.08 ± 0.11 vs. 0.18 ± 0.04; p = 0.007 and 0.08 ± 0.12 vs. 0.19 ± 0.04; p = 0.007, respectively). This finding was independent of tumor volume (p = 0.48). Furthermore, poorer initial (by scan) clinical performance scores at follow-up were found for the CCD(+) group. The presence of crossed cerebellar diaschisis in patients with diffuse glioma is associated with impaired supratentorial cerebrovascular reactivity and worse clinical outcome.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588366PMC
http://dx.doi.org/10.1007/s12311-020-01174-yDOI Listing

Publication Analysis

Top Keywords

diffuse glioma
20
patients diffuse
16
associated impaired
16
cerebrovascular reactivity
16
clinical outcome
16
crossed cerebellar
12
cerebellar diaschisis
12
diaschisis patients
8
glioma associated
8
impaired supratentorial
8

Similar Publications

Purpose: Amino acid PET with [F]-fluoroethylthyrosine ([F]FET-PET) is frequently utilized in gliomas. Most studies on prognostication based on amino acid PET comprise mixed cohorts of brain tumors with low- and high-grade features. The objective of this study was to assess the potential prognostic value of [F]FET-PET-based markers in the group of grade 2 adult-type diffuse gliomas, as defined by the WHO CNS 2021 classification.

View Article and Find Full Text PDF

ObjectivesThe objective of this study was to evaluate the occurrence of voltage-gated potassium channel (VGKC) antibodies and the pattern of MRI changes in cats with complex partial seizures with orofacial involvement (CPSOFI), as well as to investigate whether there are factors influencing survival that could be used as prognostic markers in those cats.MethodsCats with CPSOFI were identified retrospectively. The following data were retrieved from the hospital database: signalment, age at first seizure and presentation, the presence of antibodies against VGKC (leucine-rich glioma inactivating factor 1 (LGI1), contactin-associated protein 2 (CASPR2)) and cerebrospinal fluid (CSF) analysis findings.

View Article and Find Full Text PDF

Evidence for cognitive compensation mechanism in the postoperative delirium: a prospective multi-modal neuroimaging cohort study.

Brain Imaging Behav

September 2025

Department of Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical University, South 4th Ring West Road 119, Fengtai District, Beijing, 100070, China.

To explore the effect of brain cognitive compensation on the pathogenesis of postoperative delirium (POD) in the frontal glioma patients. Eighty-four adult patients with unilateral frontal glioma who underwent elective craniotomy and 37 healthy controls were recruited. Primary outcomes were POD during postoperative 1-7 days, as assessed by Confusion Assessment Method.

View Article and Find Full Text PDF

Estimating Health State Utilities for IDH-Mutant Diffuse Glioma.

Pharmacoecon Open

September 2025

Acaster Lloyd Consulting Ltd, Lacon House, 84 Theobalds Rd, London, WC1X 8NL, UK.

Background: Isocitrate dehydrogenase-mutant (mIDH) gliomas are malignant central nervous system tumours. After initial resection, patients with mIDH gliomas with favourable prognosis may live without receiving oncologic treatment for years, but ultimately patients will experience recurrence and require radio- and/or chemotherapy (RT/CT). Cost-utility analyses (CUA) can explore the value of treatments that delay recurrence and initiation of RT/CT.

View Article and Find Full Text PDF